Related Experiment Videos
Understanding the genotoxicity of tamoxifen?
1Institute of Cancer Research, Haddow Laboratories, Cotswold Road, Sutton SM2 5NG, UK. davidp@icr.ac.uk
Abstract:
Tamoxifen is an anti-oestrogenic drug widely used for adjuvant therapy of breast cancer. Its use has caused an increased incidence of endometrial cancer and it is also a potent carcinogen in rat liver. Since the demonstration that tamoxifen forms covalent DNA adducts in rat liver, many investigations of its mechanism of carcinogenic action have focused on the examination of human and animal tissues for the presence of tamoxifen-DNA adducts, the identification of their structures and the determination of the metabolic pathways that lead to their formation. This article reviews the current evidence for genotoxic mechanisms for tamoxifen carcinogenicity, and discusses some inconsistencies in the data.
Insights
Tamoxifen, used for breast cancer treatment, can cause cancer by forming DNA adducts. Research investigates these genotoxic mechanisms and metabolic pathways to understand tamoxifen carcinogenicity.
Area of Science:
- Pharmacology
- Toxicology
- Molecular Biology
Background:
- Tamoxifen is a widely used anti-oestrogenic drug for breast cancer adjuvant therapy.
- Tamoxifen use is associated with increased endometrial cancer incidence and is a potent rat liver carcinogen.
- Tamoxifen is known to form covalent DNA adducts, suggesting a genotoxic mechanism for its carcinogenicity.
Purpose of the Study:
- To review the current evidence for genotoxic mechanisms of tamoxifen carcinogenicity.
- To identify tamoxifen-DNA adducts and their formation pathways.
- To discuss inconsistencies in the data regarding tamoxifen's carcinogenic action.
Main Methods:
- Examination of human and animal tissues for tamoxifen-DNA adducts.
- Identification of the structures of tamoxifen-DNA adducts.
- Determination of metabolic pathways leading to tamoxifen-DNA adduct formation.
Main Results:
- Evidence suggests tamoxifen forms covalent DNA adducts.
- Research focuses on identifying these adducts and their metabolic origins.
- Inconsistencies in the data require further investigation.
Conclusions:
- Genotoxic mechanisms involving tamoxifen-DNA adducts are a key area of research for understanding tamoxifen carcinogenicity.
- Further investigation into metabolic pathways and adduct structures is needed.
- Addressing data inconsistencies is crucial for a complete understanding.